Immunovant (NASDAQ:IMVT) COO Melanie Gloria Sells 2,036 Shares of Stock

Posted by Francis Steltz on Jul 10th, 2026

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) COO Melanie Gloria sold 2,036 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $39.55, for a total value of $80,523.80. Following the completion of the sale, the chief operating officer owned 222,357 shares in the company, valued at $8,794,219.35. The trade was a 0.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Melanie Gloria also recently made the following trade(s):

On Friday, June 26th, Melanie Gloria sold 17,714 shares of Immunovant stock. The shares were sold at an average price of $38.31, for a total value of $678,623.34.

Immunovant Trading Down 3.4%

Immunovant stock traded down $1.38 during mid-day trading on Friday, hitting $39.71. The company had a trading volume of 1,095,102 shares, compared to its average volume of 1,648,906. The stock’s 50 day moving average price is $33.40 and its two-hundred day moving average price is $28.67. Immunovant, Inc. has a 12 month low of $14.32 and a 12 month high of $41.23. The company has a market capitalization of $8.15 billion, a PE ratio of -14.28 and a beta of 0.76.

Immunovant (NASDAQ:IMVT – Get Free Report) last released its earnings results on Wednesday, May 20th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.13). During the same period in the previous year, the firm earned ($0.64) earnings per share. Equities research analysts anticipate that Immunovant, Inc. will post -2.65 EPS for the current year.

Institutional Trading of Immunovant

A number of hedge funds have recently bought and sold shares of IMVT. Geneos Wealth Management Inc. purchased a new position in Immunovant in the fourth quarter worth about $25,000. Strs Ohio bought a new position in shares of Immunovant in the 1st quarter worth approximately $27,000. PNC Financial Services Group Inc. lifted its stake in shares of Immunovant by 138.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company’s stock worth $46,000 after purchasing an additional 1,646 shares during the period. Quarry LP boosted its holdings in shares of Immunovant by 94.9% in the fourth quarter. Quarry LP now owns 3,000 shares of the company’s stock worth $76,000 after buying an additional 1,461 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Immunovant by 228.9% during the second quarter. Tower Research Capital LLC TRC now owns 6,140 shares of the company’s stock valued at $98,000 after buying an additional 4,273 shares during the period. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on IMVT shares. Weiss Ratings restated a “sell (d-)” rating on shares of Immunovant in a research note on Monday. Bank of America upped their target price on shares of Immunovant from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. The Goldman Sachs Group increased their price target on shares of Immunovant from $29.00 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Guggenheim raised their price target on shares of Immunovant from $44.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Finally, Citigroup boosted their price objective on shares of Immunovant from $57.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $39.70.

Read Our Latest Analysis on IMVT

Immunovant Company Profile

(Get Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.